Small molecules targeting cGAS-STING pathway for autoimmune disease.
Eur J Med Chem
; 238: 114480, 2022 Aug 05.
Article
in En
| MEDLINE
| ID: mdl-35635952
ABSTRACT
Autoimmune diseases represent a class of over 80 illnesses with high incidence and prevalence and share a common pathogenesis of immune system disorders and self-attack. Over the past decade, extensive studies have demonstrated that imbalance of cGAS-STING mediated innate immune signaling is closely involved in autoimmune diseases. Over-activation of cGAS-STING pathway by mutations of STING or several exonucleases can cause accumulation of interferon and systemic inflammation. Therefore, suppression of the upregulated cGAS-STING pathway holds great potential in the treatment of human inflammatory and autoimmune diseases. Inhibitors targeting cGAS, STING and the downstream factors have been developed and pharmacologically evaluated recently. Herein, we summarize the recent advance on development of small molecular inhibitors targeting the key effectors in cGAS-STING axis as promising treatment for autoimmune diseases.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Autoimmune Diseases
/
Membrane Proteins
Type of study:
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Eur J Med Chem
Year:
2022
Document type:
Article